- Home
- CPRX vs WGS Comparison
CPRX vs WGS Comparison
Compare CPRX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- WGS
- Stock Information
- Founded
- CPRX 2002
- WGS 2017
- Country
- CPRX United States
- WGS United States
- Employees
- CPRX N/A
- WGS N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- CPRX Health Care
- WGS Technology
- Exchange
- CPRX Nasdaq
- WGS Nasdaq
- Market Cap
- CPRX 2.6B
- WGS 2.4B
- IPO Year
- CPRX 2006
- WGS N/A
- Fundamental
- Price
- CPRX $21.29
- WGS $129.08
- Analyst Decision
- CPRX Strong Buy
- WGS Strong Buy
- Analyst Count
- CPRX 5
- WGS 9
- Target Price
- CPRX $33.20
- WGS $112.22
- AVG Volume (30 Days)
- CPRX 1.4M
- WGS 476.0K
- Earning Date
- CPRX 11-05-2025
- WGS 10-28-2025
- Dividend Yield
- CPRX N/A
- WGS N/A
- EPS Growth
- CPRX 183.96
- WGS N/A
- EPS
- CPRX 1.65
- WGS 0.05
- Revenue
- CPRX $558,499,000.00
- WGS $362,321,000.00
- Revenue This Year
- CPRX $16.59
- WGS $36.01
- Revenue Next Year
- CPRX $8.80
- WGS $19.01
- P/E Ratio
- CPRX $12.72
- WGS $2,632.97
- Revenue Growth
- CPRX 28.55
- WGS 48.70
- 52 Week Low
- CPRX $19.05
- WGS $55.17
- 52 Week High
- CPRX $26.58
- WGS $136.00
- Technical
- Relative Strength Index (RSI)
- CPRX 57.67
- WGS 59.05
- Support Level
- CPRX $20.66
- WGS $115.68
- Resistance Level
- CPRX $21.55
- WGS $130.61
- Average True Range (ATR)
- CPRX 0.57
- WGS 7.29
- MACD
- CPRX 0.05
- WGS 0.79
- Stochastic Oscillator
- CPRX 84.24
- WGS 83.29
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.